SARS-CoV-2: Neutralization of BA.1 and BA.2 by therapeutic monoclonal antibodies

Scientists studied the sensitivity of Omicron BA.1 and BA.2 to nine monoclonal antibodies, some of which are used in pre-exposure prophylaxis in immunocompromised individuals. The scientists showed a loss of neutralizing activity against BA.1 and BA.2 in people treated with two antibody cocktails.